Edwards Lifesciences reported $6.51B of revenue over the trailing twelve months, +15% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $6.51B (to Q2 2026). Net income: $1.00B, trailing twelve months to Q2 2026. Free cash flow: $1.43B, trailing twelve months to Q2 2026. Operating margin: 22%, trailing twelve months to Q2 2026.

EWEdwards Lifesciences

Healthcare

$85.21+14% 1Y

$85.21

$72.6552 weeks$93.68

Latest close: back above its 200-day averageOct 9, 2026what changed →

EW as reported

Edwards Lifesciences reported $6.51B of revenue over the trailing twelve months, +15% on the year before. 11 reported series are charted on this page, each one as filed.

$6.51B

Revenue, trailing twelve months · to Q2 2026 · +15% against the twelve months before

Net income: $1.00B
Net income · −76% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.43B
Free cash flow · +144% year on year · trailing twelve months to Q2 2026
Operating margin: 22%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for EW, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$6.51B	+15%	Q2 2026
Net income	$1.00B	−76%	Q2 2026
EPS	$1.74	−75%	Q2 2026
Gross margin	78%	n/a	Q2 2026
Operating margin	22%	n/a	Q2 2026
Net margin	15%	n/a	Q2 2026
ROE	11%	n/a	Q2 2026
ROA	8.4%	n/a	Q2 2026
ROIC	16%	n/a	Q2 2026
Free cash flow	$1.43B	+144%	Q2 2026
P/E	49.0	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.